Atlas Trials

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Clinical trial NCT06592222 · COMPLETED

Trial details

NCT number
NCT06592222
Sponsor
Pfizer
Status
COMPLETED
Study type
OBSERVATIONAL
Multiple Myeloma
Start date
2024-08-26
Primary completion
2025-03-03
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.